Non-Hodgkin Lymphoma | Specialty

Predictive Biomarkers Key to Continued Progress in Non-Hodgkin Lymphoma

March 19th 2015

In an interview with OncLive, Randy Gascoyne, MD, explains how predictive biomarkers can help oncologists select the right therapies for their patients and why they are the critical next step to improving outcomes in NHL.

Dr. Randy Gascoyne on Biomarkers for Follicular Lymphoma

March 3rd 2015

Randy Gascoyne, MD, hematopathologist and research director for the Centre for Lymphoid Cancers at the BC Cancer Agency in Canada, discusses a study that investigated biomarkers for follicular lymphoma.

Sequencing Therapies in Follicular Lymphoma Requires Multifaceted Approach

February 20th 2015

The indolent nature of follicular lymphoma and the range of treatment options currently available or in development may create complicated questions regarding how to best use and sequence these therapies.

Dr. Treon on Breakthroughs in Waldenström's Macroglobulinemia

February 20th 2015

Steven Treon, MD, PhD, from the Dana-Farber Cancer Institute, discusses the game-changing discoveries in Waldenstrom's Macroglobulinemia that led to the approval of ibrutinib for treatment of the disease.

Researchers Highlight Ibrutinib Efficacy in Posttransplant, High-Risk CLL

February 18th 2015

Ibrutinib (Imbruvica) showed promising activity in heavily pretreated, relapsed/refractory chronic lymphocytic leukemia after allogeneic stem cell transplantation, according to data presented at the American Society for Blood and Marrow Transplantation 2015 BMT Tandem Meeting.

Researchers Say Breakthrough Blood Cancer Therapies Are Worth the High Cost, Other Experts Disagree

February 18th 2015

Are the high costs of breakthrough therapies for blood cancers, some with price tags of more than $100,000 per year, worth the improved outcomes for patients?

Dr. Matthew Davids On Advances in CLL

February 18th 2015

Matthew Davids, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, talks about advances in chronic lymphocytic leukemia (CLL) treatment.

Closing Thoughts: A Cure in Sight for CLL?

January 16th 2015

Treatments and Phenotypes in DLBCL

January 16th 2015

Strategies for Treating Myc-Positive DLBCL

January 16th 2015

Utility of MRD in Mantle Cell Lymphoma

January 16th 2015

Improving Outcomes in Mantle Cell Lymphoma

January 16th 2015

Translating Novel CLL Therapies to Other Types of NHL

January 16th 2015

Indolent Non-Hodgkin's Lymphoma Treatment Selection

January 16th 2015

Assessing Response With Novel Agents in CLL

January 16th 2015

Role of NOTCH1 Mutations in CLL

January 16th 2015

Novel Treatment Approaches to Relapsed/Refractory CLL

January 16th 2015

Strategies for Managing Immune Thrombocytopenia in CLL

January 16th 2015

Maintenance Therapy in Chronic Lymphocytic Leukemia

January 16th 2015

Role of Transplantation in High-Risk CLL

January 16th 2015